Screening for Amyloidosis Before Aortic Valve Elective Replacement
Condition(s) studied
Investigational drug(s) / intervention(s)
The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.: We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
Study summary
Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).
Eligibility
Primary outcome measure(s)
- Number/ proportion of ATTR cases identified by systematic screening — Enrolment period: 18 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Charité - Universitätsmedizin Berlin | Berlin | Germany |
More Charite University, Berlin, Germany trials in Germany
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04869631 on ClinicalTrials.gov ↗ ← All trials in Germany